SCHEMBL1756286

SCHEMBL1756286

COC(=O)C(NC(=O)c1ncc(-c2ccc(NC(=O)Nc3cccc(Cl)c3)cc2)o1)C(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSGALNACT1 Q8TDX6 3/20 0.54
KDR P35968 3/20 0.46
THRB P10828 1/20 0.45
DGAT1 O75907 5/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
ATM Q13315 1/20 0.43
TRPV1 Q8NER1 1/20 0.42
KIT P10721 2/20 0.42
FLT1 P17948 2/20 0.42
TEK Q02763 2/20 0.42
EGFR P00533 1/20 0.42
IGF1R P08069 1/20 0.42
MET P08581 1/20 0.42
PDGFRB P09619 1/20 0.42
FGFR1 P11362 1/20 0.42
BRAF P15056 1/20 0.42
FGFR4 P22455 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1756284 1.00 CSGALNACT1 (0.54) CSGALNACT1KDRTHRBDGAT1MEN1
SCHEMBL1756256 0.91 CSGALNACT1 (0.65) CSGALNACT1KDRDGAT1
SCHEMBL1756254 0.91 CSGALNACT1 (0.65) CSGALNACT1KDRDGAT1
SCHEMBL1756215 0.87 DGAT1 (0.59) CSGALNACT1KDRDGAT1MEN1KMT2A
SCHEMBL1756210 0.86 DGAT1 (0.55) CSGALNACT1THRBDGAT1MEN1KMT2A
SCHEMBL1756289 0.86 CSGALNACT1 (0.56) CSGALNACT1DGAT1MEN1KMT2AMAPT
SCHEMBL1756237 0.86 CSGALNACT1 (0.56) CSGALNACT1DGAT1MEN1KMT2AMAPT
SCHEMBL1756217 0.86 DGAT1 (0.56) CSGALNACT1DGAT1MEN1KMT2ANPC1
SCHEMBL1756209 0.84 DGAT1 (0.64) CSGALNACT1KDRDGAT1TUBB4ATUBB
SCHEMBL1756443 0.83 NPC1 (0.47) MEN1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722901-B2 Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity Piramal Enterprises Limited (IN) 2014-05-13 US claimed
EP-2496564-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS Piramal Life Sciences Limited (IN) 2012-09-12 EP claimed
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY Piramal Enterprises Limited (IN) 2012-08-23 US claimed
WO-2011055289-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO claimed
US-8722901-B2 Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity Piramal Enterprises Limited (IN) 2014-05-13 US disclosed
EP-2496564-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS Piramal Life Sciences Limited (IN) 2012-09-12 EP disclosed
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY Piramal Enterprises Limited (IN) 2012-08-23 US disclosed
WO-2011055289-A2 HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214854-A1 CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY DGAT1, DGAT2, DLAT CSGALNACT1 555/4885KDR 4257/4885THRB 1695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.